Alexion seeks European approval for Soliris to treat rare blood disorder

By Lisa Kerner

Charlotte, N.C., Sept. 26 - Alexion Pharmaceuticals, Inc.'s wholly owned subsidiary, Alexion Europe, has submitted a Market Authorization Application to the European Medicines Evaluation Agency for Soliris (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria, a rare, genetic blood disorder.

The Cheshire, Conn., biotechnology included data from its pivotal phase 3 trial, which met all pre-specified primary and secondary endpoints, according to a news release.

Alexion previously submitted a Biologics License Application with the Food and Drug Administration for the drug.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.